AVI BioPharma to Present Company Overview at the 13th Annual BIO CEO & Investor Conference
February 10 2011 - 8:00AM
Marketwired
AVI BioPharma (NASDAQ: AVII), a developer of RNA-based
therapeutics, announced today that Chris Garabedian, AVI's
president and CEO, will present a company overview at 10:30 a.m.
EST on Tuesday, Feb. 15, at the 13th Annual BIO CEO & Investor
Conference in New York City.
The presentation will include an update on AVI's clinical
development program for its RNA-based Duchenne muscular dystrophy
(DMD) drug candidates, including AVI-4658. AVI is developing
AVI-4658 as a treatment for a substantial subgroup of patients with
DMD, a genetic disease resulting in progressive muscle weakness
caused by the absence of functional dystrophin. The presentation
will also include updates on AVI's other programs, including AVI's
influenza program, which is being advanced with U.S. Department of
Defense funding.
The presentation at the BIO CEO & Investor Conference will
be Webcast live under the events section of AVI's Web site at
www.avibio.com and will be archived there following the
presentation. Please connect to AVI's Web site several minutes
prior to the start of the broadcast to ensure adequate time for any
software download that may be necessary.
AVI also announced that the company will report its
fourth-quarter and year-end 2010 financial results on Thursday,
March 10. The company plans to host a conference call and Webcast
on that day.
About AVI BioPharma AVI BioPharma is
focused on the discovery and development of novel RNA-based
therapeutics for rare and infectious diseases, as well as other
select disease targets. Applying pioneering technologies developed
and optimized by AVI, the Company is able to target a broad range
of diseases and disorders through distinct RNA-based mechanisms of
action. Unlike other RNA-based approaches, AVI's technologies can
be used to directly target both messenger RNA (mRNA) and precursor
messenger RNA (pre-mRNA) to either down-regulate (inhibit) or
up-regulate (promote) the expression of targeted genes or proteins.
By leveraging its highly differentiated technology platform, AVI
has built a pipeline of potentially transformative therapeutic
agents, including a clinical stage Duchenne muscular dystrophy
candidate and anti-infective candidates for influenza and
hemorrhagic fever viruses. For more information, visit
www.avibio.com.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking,
including statements about the planning and clinical development of
AVI's RNA-based therapeutics for Duchenne muscular dystrophy,
including AVI 4658, and AVI's U.S. Department of Defense supported
flu program. These forward-looking statements involve risks and
uncertainties, many of which are beyond AVI's control. Known risk
factors include, among others: clinical trials may not be initiated
or proceed on expected timelines; clinical trials may not
demonstrate safety and efficacy of any of AVI's drug candidates,
including AVI 4658, and/or AVI's RNA-based technology platform; any
of AVI's drug candidates, including AVI 4658, may fail in
development, may not receive required regulatory approvals, or be
delayed to a point where they do not become commercially viable.
Any of the foregoing risks could materially and adversely affect
AVI's business, results of operations and the trading price of its
common stock. For a detailed description of risks and uncertainties
AVI faces, you are encouraged to review the official corporate
documents filed with filed with the Securities and Exchange
Commission. AVI does not undertake any obligation to publicly
update its forward-looking statements based on events or
circumstances after the date hereof.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024